How's everyone doing with Entresto?

Discussion in 'Novartis' started by anonymous, Jul 31, 2015 at 2:08 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Any scripts yet anyone? I've had samples and vouchers used but no scripts that I know of. Most docs interested, about 10% super interested.
     

  2. anonymous

    anonymous Guest

    You mean mystery flavor diovan? :eek:
     
  3. anonymous

    anonymous Guest

    i've had a lot of interest but no Rx's yet. Feel the Rx's will come but probably not as fast as the company wants. Feel comfortable that things will be picking up in next few weeks
     
  4. anonymous

    anonymous Guest

    To the mystery Diovan responder, and this is a serious question...why do yo work here with an attitude like that? Leave and give an opportunity to someone else!
     
  5. anonymous

    anonymous Guest

    I agree
     
  6. anonymous

    anonymous Guest

    I doubt the mystery Diovan responder is a Novartian.
     
  7. anonymous

    anonymous Guest

    What attitude? Let's see
    Diovan has been combined with:

    HCT
    Amlodipine
    Tekturna
    Amlodipine & HCT
    Sacubitril

    So what exactly is your shock & dismay over?
    If you throw in the plethora of doses you have what like
    3 dozen different diovan flavors?

    Now you have another.
    Hey that's the sales pitch
    Diovan, more flavors than Baskin Robbins :confused:
     
  8. anonymous

    anonymous Guest

     
  9. anonymous

    anonymous Guest

    Exactly. Another pathetic attempt at profiteering of a pharma company. It's embarrassing trying to talk to any intelligent person about this crap. Donovan goes generic and we counter with this crap. Novartis sunk to new lows with this joke.
    Shows you what the FDA is.....incompetent and corrupt?
     
  10. anonymous

    anonymous Guest

    Be patient the Japanese trials will begin anew :rolleyes:
     
  11. Diovan NI

    Diovan NI Guest

    The 88th diovan combo. Hoo Rah
    oops sorry mean untrusto
     
  12. anonymous

    anonymous Guest

    Listen. I came here for Gilenya, by far an oral MS drug that should have taken the MS market by storm......and it didn't. Novartis is full of toxic recycled trash as leadership. The people we've gone though is astounding. Your screwed, you have a half assed drug and the same clowns steering the ship. It's not the drug, reps, it's the people in home office....they couldn't lead a horse to water let alone launch a product successfully. I'm out of here in two weeks and like many before me for the right reason.......they don't get it. Bad leaders, lead to bad results......it's simple. But then again, what do I know......I'm a simple rep....
     
  13. anonymous

    anonymous Guest

    Everything is done for the Stock/investors. All these smoke & mirrors marketing practices & hollow projections mean nothing. Duping the institutional investors so the execs make millions off options & float away with their golden parachutes is the name of the game. The rest of the crap is just vapid sound bytes absorbed by dull witted buffoons not unlike what politicians do.
     
  14. anonymous

    anonymous Guest

    Great drug with doctors highly interested...goals are just too high to make any real money.
     
  15. Rinse repeat

    Rinse repeat Guest

    DumbTrusto - the sequel to............

    BOSTON (MarketWatch) -- Under a proposed agreement, Bristol-Myers has agreed to pay $185 million to settle shareholder suits filed over the company's handling of its now-defunct drug omapatrilat, or Vanlev.

    In a release early Thursday, Bristol-Myers said a federal court has given preliminary approval to an agreement that calls for the drugmaker to pay $185 million into a settlement fund. Settlements would then be made from the fund to claimants who purchased Bristol-Myers stock between October 19, 1999 and March 20, 2002.

    The legal settlement also calls for Bristol-Myers to commit to publicly disclosing certain clinical trial results and clinical trial registrations via a publicly-accessible database.

    Bristol-Myers added that the settlement does not require the drugmaker to admit to any wrongdoing.
     
  16. anonymous

    anonymous Guest

    I'd rather sell a mediocre drug with somewhat attainable goals than this!
     
  17. anonymous

    anonymous Guest

    You do have a mediocre drug
     
  18. anonymous

    anonymous Guest

    Maybe my young Cards are different. I got 5 out of my top dog already
     
  19. anonymous

    anonymous Guest

    Only 495 more to go...
     
  20. anonymous

    anonymous Guest

    I've had a few patients starts so far and more to come. Naysayers are probably Amgen douche bags or disgruntled ex Novartis employees. I'd you're panicking already, you probably shouldn't be in sales.. good luck to you